Plus Therapeutics Inc represents a strong commitment to innovation, integrity, and patient well-being. With a focus on delivering life-changing therapeutics, the company strives to create value for both patients and investors. Their corporate philosophy is founded on scientific excellence, ethical practices, and a patient-centric approach. Plus Therapeutics Inc actively seeks groundbreaking solutions to address unmet medical needs, leveraging cutting-edge technologies and strategic partnerships. By driving forward with a compassionate and results-driven mindset, Plus Therapeutics Inc aims to contribute positively to the healthcare industry and improve the lives of patients worldwide.

Plus Therapeutics Inc is primarily present in the United States.

Some significant milestones that Plus Therapeutics Inc has achieved include the development of its lead product candidate, Rhenium NanoLiposomes (RNL™), which is a potential treatment for recurrent glioblastoma. The company has also received Orphan Drug Designation from the U.S. FDA for RNL™ in the treatment of glioblastoma. Plus Therapeutics Inc has successfully completed preclinical studies and initiated a Phase 1 clinical trial for RNL™. In addition, the company has strengthened its financial position by securing grants and raising funds through public offerings.

Plus Therapeutics Inc is a pharmaceutical company focused on developing and commercializing innovative and targeted therapies for rare diseases. Established in 1997 as CytoGenix Inc, the company evolved into a drug development entity with a strong emphasis on precision oncology and rare diseases. Plus Therapeutics is committed to improving patient outcomes through its unique expertise in nanotechnology and its proprietary drug delivery platform. With a dedicated team of scientists and researchers, the company strives to advance its pipeline of therapeutic candidates. Plus Therapeutics Inc is dedicated to providing novel treatment options for patients in need and making a positive impact in the field of healthcare.

Some of the main competitors of Plus Therapeutics Inc in the market include biopharmaceutical companies such as Pfizer Inc, Novartis AG, Merck & Co. Inc, and Amgen Inc.

Plus Therapeutics Inc is primarily active in the pharmaceutical industry.

The business model of Plus Therapeutics Inc is focused on developing and commercializing innovative, targeted therapies for the treatment of rare cancers. They utilize cutting-edge nanotechnology platforms to formulate their drugs, enhancing their efficacy and reducing potential side effects. Plus Therapeutics aims to address unmet medical needs by providing patients with personalized and targeted treatment options. Through partnerships and collaborations, they strive to advance their drug candidates and bring them to market efficiently. Overall, Plus Therapeutics Inc's business model revolves around research, development, and commercialization of advanced therapies for rare cancers.

Det Plus Therapeutics P/E-forhold er -0,45.

Plus Therapeutics KUV er 1,06.

AlleAktien Kvalitetsscore for Plus Therapeutics er 4/10.

Den forventede Plus Therapeutics omsætning er 5,17 mio. USD.

Den forventede Plus Therapeutics indtjening er -12,11 mio. USD.

Plus Therapeutics Inc is an innovative biopharmaceutical company specializing in the development and commercialization of chemotherapy products and immunotherapy solutions for the treatment of cancer. The company is headquartered in Austin, Texas, and was founded in 2011. Plus Therapeutics' main focus is on the development of nanoparticle medicines that are intended to provide higher effectiveness at lower dosages. This development aims to improve the quality of life for cancer patients while also reducing therapy costs. Plus Therapeutics specializes in integrating this technology into a wide range of chemotherapeutics such as doxorubicin or cisplatin in order to create novel therapeutic solutions. Another focus of the company is the development of immunotherapies targeting the discovery and combat of cancer cells. The company utilizes innovative technologies, such as antibody conjugates, to achieve specific and targeted drug delivery. Plus Therapeutics has also specialized in the development of radiolabeled conjugates enabling targeted tumor combat. By utilizing these conjugates, surgical procedures and traditional radiation therapy can be avoided, which can be more cost-effective for both patients and hospitals. The company has multiple treatment options for different types of cancer in its product portfolio. An important aspect of Plus Therapeutics' business model is collaborations with other companies and research institutions. These collaborations aim to further develop the technologies and explore new markets. Additionally, partnerships with the scientific community are meant to accelerate drug development and improve effectiveness. Plus Therapeutics accordingly invests in research and development of talented professionals to expand its scientific expertise. Recently, Plus Therapeutics is on its way to accelerate growth with its recently acquired subsidiary, Cognate BioServices Inc. Cognate BioServices is a company specializing in the clinical manufacturing of cell therapy products. The acquisition is intended to help expand capabilities in the field of clinical cell manufacturing, thereby taking collaboration with other companies and research institutions in the field of cell therapies to a new level. Plus Therapeutics has established a dynamic business model focused on the development of innovative technologies and collaboration with other companies and research institutions. Through the research and development of new drug products, a clear goal is to achieve improved quality of life and cost reduction for cancer patients.

Plus Therapeutics udbetaler et udbytte på 0 USD fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Plus Therapeutics, eller selskabet udbetaler ikke udbytte.

ISIN'en for Plus Therapeutics er US72941H4002.

WKN for Plus Therapeutics er A2PPX6.

Tickeren for Plus Therapeutics er PSTV.

I løbet af de sidste 12 måneder betalte Plus Therapeutics en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil Plus Therapeutics sandsynligvis betale en dividende på 0 USD.

Udbytteafkastet for Plus Therapeutics er i øjeblikket .

Plus Therapeutics betaler kvartalsvis udbytte. Dette uddeles i månederne .

Plus Therapeutics betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 USD. Dette svarer til et dividendeafkast på 0 %.

Plus Therapeutics bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på Plus Therapeutics fra den 27.7.2024 på 0 USD, skulle du have haft aktien i din portefølje før ex-datoen den 27.7.2024.

Udbetalingen af det sidste udbytte blev foretaget den 27.7.2024.

I løbet af 2023 udbetalte Plus Therapeutics 0 USD i form af dividender.

Udbytterne fra Plus Therapeutics udbetales i USD.